Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors

Fecha de publicación: 01/05/2016

Autores de IIS La Fe

• Ana Rosa Cid Haro

  Autor

Participantes ajenos a IIS La Fe

• Mingot-Castellano, ME
• Alvarez-Roman, MT
• Lopez-Fernandez, MF
• Altisent-Roca, C
• Canaro-Hirnyk, MI
• Jimenez-Yuste, V
• Perez-Garrido, R
• Sedano-Balbas, C

Grupos

• Hemostasia, Trombosis, Arteriosclerosis y Biología vascular

  

  Investigador Principal

  Pilar Medina Badenes

Abstract

IntroductionPatients with severe haemophilia and inhibitors against factor VIII who require surgery need a prophylactic approach to prevent bleeding complications. Scientific evidence to decide the best prophylactic treatment is very limited and mainly based on retrospective or case series. AimsTo develop evidence- and expert opinion-based guidelines for prophylactic therapy for patients with haemophilia and inhibitors undergoing surgery. MethodsA panel of nine Spanish haematologists undertook a systematic review of the literature and selected publications providing relevant information regarding the prophylactic management of patients with haemophilia and inhibitors undergoing dental extraction, minor surgery or major surgery. ResultsAlthough evidence is very limited, the panel considers that it seems advisable that prophylaxis should be given in most cases with a bypassing agent (aPCC or rFVIIa) and should start immediately before minor or major surgery. Patients should be closely monitored to enable dose/product modification as needed. ConclusionIt is necessary to communicate clinical experience in a detailed way in order to ensure optimal schemes of prophylaxis for patients with haemophilia and inhibitors. Development of objective outcomes to evaluate efficacy is crucial.

Keywords

• prophylaxis; surgery haemophilia; inhibitors; consensus